Premium
Oral desmopressin treatment of central diabetes insipidus in children
Author(s) -
Boulgourdjian EM,
Martínez AS,
Ropelato MG,
Heinrich JJ,
Bergadá C.
Publication year - 1997
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.1997.tb14858.x
Subject(s) - medicine , desmopressin , nocturia , diabetes insipidus , antidiuretic , urinary system , diabetes mellitus , urology , plasma osmolality , pediatrics , endocrinology , vasopressin
To assess the efficacy of treatment with oral desmopressin (DDAVP), 20 patients, aged 5–20 y, with central diabetes insipidus were studied during 3 d of hospitalization and for 3 months at the outpatient clinic. At baseline the median rate of diuresis was 12. 7 ml kg ‐1 h ‐1 . Urinary output decreased significantly under treatment with an increase in urinary osmolality, normalization of plasma osmolality and absence of nocturia. Patients were discharged from hospital with a median dose of 500μg d ‐1 (100–1200μg d ‐1 ). An adjustment in dosage was necessary in seven patients during follow‐up, resulting in a final dose of 600μg d ‐1 . Body weight and DDAVP doses ( r = 0. 75, p = 0. 001) and body surface and DDAVP doses ( r = 0. 72, p < 0. 001) were significantly correlated. The average dosage was 474 ± 222μg m ‐2 d ‐1 (mean ± SD). The oral DDAVP treatment remained effective during the 3 months of follow‐up. This therapy offers an alternative for the treatment of central diabetes insipidus in children.